August 3, 2023
Celsius Therapeutics (President and CEO: Tariq Kassum, MD; Headquarters: Cambridge, USA; hereinafter referred to as “Celsius”), a biotechnology company pioneering new precision medicines for patients with inflammatory disease by harnessing the power of single-cell RNA sequencing and human biology at scale, today announced the initiation of dosing in the company’s first-in-human Phase 1 clinical trial of CEL383 in healthy volunteers. CEL383 is a potential first-in-class anti-TREM1 antibody that Celsius is advancing for the treatment of inflammatory bowel disease (IBD).
Celsius has taken a novel approach to understanding immuno-inflammatory disease through a powerful combination of single-cell genomics and machine learning. The company has successfully scaled its SCOPE (Single Cell Observations for Precision Effect) platform which enables them to discover therapeutic targets of high interest in complex, multifactorial diseases such as IBD and solid tumors. TREM1 is the first of these targets, an amplifier of mucosal inflammation situated at the intersection of the microbiome and the immune system.
Fast Track Initiative invested in Celsius as its first overseas investment in 2022 and firmly believes in the company’s trajectory and its capacity to make significant contributions to the biotechnology landscape, pushing the boundaries of precision medicine into new territory.
To view the official Press Release, visit Celsius Therapeutics Press Release
About Celsius Therapeutics
Celsius Therapeutics is a clinical-stage biotechnology company developing novel precision medicines in inflammatory disease by harnessing the power of single cell RNA sequencing and human biology at scale. The company’s first therapeutic candidate is an anti-TREM1 antibody for the treatment of IBD. Celsius is based in Cambridge, Mass. For more information, please visit https://celsiustx.com, or follow us on LinkedIn or Twitter.
About Fast Track Initiative:
Established in 2004, Fast Track Initiative, Inc. (FTI) is a life science venture capital firm focusing its investments on early-stage startups with a strong focus on biotech and therapeutics. FTI has a strict mission to make a ground-breaking impact on the quality of our life and human wellness through investments across a broad range of areas in the life science community including therapeutics, diagnostics, digital health, healthcare services, and more. The company provides valuable, hands-on support to its 30+ portfolio companies through business and R&D strategy, partnering, investor syndication, and more, including access to its network of professionals in Japan.
Visit https://us.fasttrackinitiative.com for more details, or follow us on LinkedIn: https://www.linkedin.com/company/fast-track-initiative/
Media Contact:
For press inquiries or investor inquiries, please email: message.us@fasttrackinitiative.com
